Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 8/20 | 0.60 |
| ▸ | CYP2A6 | P11509 | 6/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | NCK1 | P16333 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL607927 | 0.92 | CYP1A2 (0.71) | CYP1A2CYP2A6ALDH1A1HSD17B10HPGD | |
| SCHEMBL597341 | 0.89 | CYP1A2 (0.67) | CYP1A2CYP2A6ALDH1A1HSD17B10HPGD | |
| SCHEMBL599276 | 0.89 | CYP1A2 (0.65) | CYP1A2CYP2A6ALDH1A1HSD17B10HPGD | |
| SCHEMBL30694959 | 0.89 | CYP1A2 (0.65) | CYP1A2CYP2A6ALDH1A1HSD17B10HPGD | |
| SCHEMBL598560 | 0.85 | CYP1A2 (0.62) | CYP1A2CYP2A6ALDH1A1HSD17B10HPGD | |
| SCHEMBL216959 | 0.85 | CYP2A6 (0.65) | CYP1A2CYP2A6ALDH1A1HSD17B10HPGD | |
| SCHEMBL30540087 | 0.85 | CYP2A6 (0.65) | CYP1A2CYP2A6ALDH1A1HSD17B10HPGD | |
| SCHEMBL9475999 | 0.84 | CYP1A2 (0.48) | CYP1A2CYP2A6ALDH1A1HSD17B10HPGD | |
| SCHEMBL25641416 | 0.84 | CYP1A2 (0.45) | CYP1A2CYP2A6ALDH1A1HSD17B10HPGD | |
| SCHEMBL599225 | 0.83 | HPRT1 (0.64) | CYP1A2CYP2A6ALDH1A1HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250019593-A1 | RENEWABLE DIESEL PRODUCTION FROM CATALYTIC PYROLYSIS FEEDSTOCK | IFP Energies Nouvelles (FR) | 2025-01-16 | — | — | US | disclosed |
| US-20250011655-A1 | RENEWABLE JET PRODUCTION FROM CATALYTIC PYROLYSIS FEEDSTOCK | IFP Energies Nouvelles (FR) | 2025-01-09 | — | — | US | disclosed |
| EP-4433552-A1 | RENEWABLE DIESEL PRODUCTION FROM CATALYTIC PYROLYSIS FEEDSTOCK | IFP Energies nouvelles (FR) | 2024-09-25 | — | — | EP | disclosed |
| EP-4433553-A1 | RENEWABLE JET PRODUCTION FROM CATALYTIC PYROLYSIS FEEDSTOCK | IFP Energies nouvelles (FR) | 2024-09-25 | — | — | EP | disclosed |
| CN-118302504-A | Preparation of renewable jet fuel from catalytic pyrolysis feedstock | IFP 新能源公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118265764-A | Preparation of renewable diesel from catalytic pyrolysis feedstock | IFP 新能源公司 | 2024-06-28 | — | — | CN | disclosed |
| WO-2024117859-A1 | COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | 솔루스첨단소재 주식회사 | 2024-06-06 | — | — | WO | disclosed |
| WO-2023088772-A1 | RENEWABLE JET PRODUCTION FROM CATALYTIC PYROLYSIS FEEDSTOCK | IFP Energies Nouvelles (FR) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023088771-A1 | RENEWABLE DIESEL PRODUCTION FROM CATALYTIC PYROLYSIS FEEDSTOCK | IFP Energies Nouvelles (FR) | 2023-05-25 | — | — | WO | disclosed |
| US-10753831-B2 | Method for detection of air-water exchange flux | GUANGZHOU INSTITUTE OF GEOCHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2020-08-25 | — | — | US | disclosed |
| EP-1569652-A4 | N SP 4 /SP-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | PHARMASSET INC (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | GILEAD PHARMASSET LLC | 2007-04-05 | — | — | US | disclosed |
| US-7105527-B2 | N4-acylcytosine nucleosides for treatment of viral infections | GILEAD PHARMASSET LLC | 2006-09-12 | — | — | US | disclosed |
| EP-1569652-A2 | N SP 4 /SP-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | Pharmasset Ltd. (BB) | 2005-09-07 | — | — | EP | disclosed |
| US-6908924-B2 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | PHARMASSET, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20040214844-A1 | N4-acylcytosine nucleosides for treatment of viral infections | GILEAD PHARMASSET LLC | 2004-10-28 | — | — | US | disclosed |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | GILEAD PHARMASSET LLC | 2003-09-18 | — | — | US | disclosed |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | PHARMASSET, INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2003063771-A2 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | PHARMASSET LTD. (BB) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003051306-A2 | N4-ACYLCYTOSINE-1,3-DIOXOLANE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | ENTPD5, DUT, NT5C3B | CYP1A2 1240/4885CYP2A6 1327/4885ALDH1A1 2325/4885 |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | ENTPD5, CDA, ADA | CYP1A2 810/4885CYP2A6 1101/4885ALDH1A1 645/4885 |
| US-20040214844-A1 | N4-acylcytosine nucleosides for treatment of viral infections | ENTPD5, DUT, PNP | CYP1A2 1161/4885CYP2A6 1193/4885ALDH1A1 2002/4885 |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | DERA, DPYD, DHPS | CYP1A2 592/4885CYP2A6 1024/4885ALDH1A1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.